Brought to you by 
Mylan involved in another unsolicited offer, this time as target for Teva; withdrawn
20 Sep 2017
Executive Summary
On the same day that generics/OTC firm Perrigo Co. PLC's board unanimously rejected an unsolicited offer to be acquired by fellow public generics company Mylan NV for approximately $29bn, Mylan itself received an unsolicited proposal to be bought by Teva Pharmaceutical Industries Ltd. in a deal worth $40bn, or $82 per share (a 21% premium), evenly split between cash and Teva stock. Rumors about a Teva bid for Mylan surfaced in March 2015.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Transdermal
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan involved in another unsolicited offer, this time as target for Teva; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice